Alnylam shares down 4.9% premarket after rival trial data

Alnylam Pharmaceuticals (ALNY) shares fell 4.9% in premarket trading following the release of data from a rival trial, marking a reversal from recent gains driven by setbacks in competing therapies for ATTR cardiomyopathy. Despite the recent rally, Alnylam’s stock has declined 25.34% year to date, though it has delivered a 5-year total shareholder return of 68.28%. The company’s AMVUTTRA therapy has shown strong uptake in its first full quarter post-approval, with broad payer access and low patient costs supporting its market potential. Analysts suggest that international expansion in key markets such as Germany, Japan, and Brazil could drive additional revenue in the coming months. However, the recent drop highlights ongoing uncertainty about whether the stock’s recent volatility reflects a stronger business outlook or shifting investor sentiment. The most widely followed narrative still assigns a fair value of $434.72, implying a potential undervaluation of 31.3%. Investors will be watching closely for signs that Alnylam can sustain its growth trajectory and meet the expectations embedded in its valuation.